Skip to main content

97 - References

References

104 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

  1. Knox ED, et al. Clinical review of a long-­acting, injectable formulation of risperidone. Clin Ther 2004; 26:1994–2002.
  2. Wilson WH. A visual guide to expected blood levels of long-­acting injectable risperidone in clinical practice. J Psychiatr Pract 2004; 10:393–401.
  3. Royal Pharmaceutical Society. Psychotropic Drug Directory. Pharmaceutical Press; 2024 (last accessed May 2024); https://www.pharmaceuticalpress.com/products/psychotropic-­drug-­directory.
  4. Datapharm. Electronic Medicines Compendium. 2024 (last accessed February 2025); https://www.medicines.org.uk/emc.
  5. Nesvag R, et al. Serum concentrations of risperidone and 9-­OH risperidone following intramuscular injection of long-­acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 2006; 114:21–26.
  6. Janssen-­Cilag Ltd. Summary of Product Characteristics. Xeplion (paliperidone) 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg prolonged-­release suspension for injection. 2023 (last accessed May 2024); https://www.medicines.org.uk/emc/product/7652/smpc.
  7. ROVI Biotech Limited. Summary of Product Characteristics. Okedi (risperidone) 100mg powder and solvent for prolonged-­release suspension for injection pre-­filled syringes. 2023 (last accessed August 2024); https://www.medicines.org.uk/emc/product/13778/smpc.
  8. Shandong Luye Pharmaceutical Co Ltd. Highlights of Prescribing Information. RYKINDO® (risperidone) for extended-­release injectable suspension for intramuscular use. 2023 (last checked June 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212849s000lbl.pdf.
  9. Correll CU, et  al. Efficacy and safety of once-­monthly Risperidone ISM(®) in schizophrenic patients with an acute exacerbation. NPJ Schizophr 2020; 6:37.
  10. Álamo C. Risperidone ISM as a new option in the clinical management of schizophrenia: a narrative review. Adv Ther 2022; 39: 4875–4891.
  11. Sánchez P, et al. Extrapyramidal adverse events and anticholinergics use after the long-­term treatment of patients with schizophrenia with the new long-­acting antipsychotic Risperidone ISM(®): results from matching-­adjusted indirect comparisons versus once-­monthly formulations of paliperidone palmitate and aripiprazole monohydrate in 52-­week studies. Ann Gen Psychiatry 2023; 22:33.
  12. US Food and Drug Administration. Cross-­Discipline Team Leader Review. RBP-­7000 (risperidone-­ATRIGEL). 2018 (last accessed February 2025); https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210655Orig1s000SumR.pdf.
  13. Walling DP, et al. An open-­label study to assess monthly risperidone injections (180 mg) following switch from daily oral risperidone (6 mg) in stable schizophrenic patients. Clin Drug Investig 2024; 44:251–260.
  14. Invidior UK Limited. Highlights of Prescribing Information. Perseris (risperidone) for extended-­release suspension, for subcutaneous use. 2022 (last checked June 2024); https://www.perserishcp.com/prescribing-­information.pdf.
  15. Højlund M, et al. Switching to long-­acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opin Pharmacother 2023; 24:1463–1489.
  16. Tchobaniouk LV, et al. Once-­monthly subcutaneously administered risperidone in the treatment of schizophrenia: patient considerations. Patient Prefer Adherence 2019; 13:2233–2241.
  17. Nasser AF, et al. Efficacy, safety, and tolerability of rbp-­7000 once-­monthly risperidone for the treatment of acute schizophrenia: an 8-­week, randomized, double-­blind, placebo-­controlled, multicenter phase 3 study. J Clin Psychopharmacol 2016; 36:130–140.
  18. Le Moigne A, et al. Reanalysis of a phase 3 trial of a monthly extended-­release risperidone injection for the treatment of acute schizophrenia. J Clin Psychopharmacol 2021; 41:76–77.
  19. Andorn A, et al. Monthly extended-­release risperidone (rbp-­7000) in the treatment of schizophrenia: results from the phase 3 program. J Clin Psychopharmacol 2019; 39:428–433.
  20. Le Moigne A, et al. PANSS individual item and marder dimension analyses from a pivotal trial of RBP-­7000 (monthly extended-­release risperidone) in schizophrenia patients. J Clin Psychiatry 2021; 82:21m13906.
  21. Indivior UK Limited. Highlights of Prescribing Information: Perseris (risperidone) for extended-­release injectable suspension, for subcutaneous use. 2018 (last accessed June 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210655s000lbl.pdf.
  22. Citrome L. Sustained-­release risperidone via subcutaneous injection: a systematic review of RBP-­7000 (PERSERIS™) for the treatment of schizophrenia. Clin Schizophr Relat Psychoses 2018; 12:130–141.
  23. Teva Neuroscience Inc. Highlights of Prescribing Information. UZEDY (risperidone) extended-­release injectable suspension for subcutaneous use. 2024 (last checked June 2024); https://www.uzedy.com/globalassets/uzedy/prescribing-­information.pdf.
  24. Clinical Trials.gov. Study to Evaluate TV-­46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia (RISE). 2023 (last accessed February 2025); https://clinicaltrials.gov/study/NCT03503318.
  25. Clinical Trials.gov. A Study to Test if TV-­46000 is Safe for Maintenance Treatment of Schizophrenia (SHINE). 2022 (last accessed February 2025); https://classic.clinicaltrials.gov/ct2/show/NCT03893825.
  26. Kane JM, et al. A long-­term safety and tolerability study of tv-­46000 for subcutaneous use in patients with schizophrenia: a phase 3, randomized, double-­blinded clinical trial. CNS Drugs 2024; 38:625–636.
  27. Kane JM, et al. Efficacy and safety of TV-­46000, a long-­acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry 2023; 10:934–943.
  28. Karas A, et al. Perseris(TM): A new and long-­acting, atypical antipsychotic drug-­delivery system. P T 2019; 44:460–466.
  29. Dexcel Pharma Ltd. Summary of Product Characteristics. Risperidone 1mg Film-­Coated Tablets. 2023 (last checked May 2024); https:// www.medicines.org.uk/emc/product/8207/smpc.
  30. Janssen Pharmaceutical Companies. Highlights of Prescribing Information: RISPERDAL® (risperidone) tablets, RISPERDAL® (risperidone) oral solution, RISPERDAL® M-­TAB® (risperidone) orally disintegrating tablets. 2019 (last checked May 2024); https://www.accessdata.fda. gov/drugsatfda_docs/label/2019/020272s082,020588s070,021444s056lbl.pdf.

Schizophrenia and related psychoses CHAPTER 1 31. Janssen-­Cilag Limited. Summary of Product Characteristics. Invega (paliperidone) 3 mg prolonged-­release tablets. 2021 (last checked May 2024); https://www.medicines.org.uk/emc/product/6816. 32. Walling DP, et  al. The steady-­state comparative bioavailability of intramuscular risperidone ISM and oral risperidone: an open-­label, ­one-­sequence study. Drug Des Devel Ther 2021; 15:4371–4382. 33. Perlstein I, et al. Population pharmacokinetic modeling and simulation of tv-­46000: a long-­acting injectable formulation of risperidone. Clin Pharmacol Drug Dev 2022; 11:865–877. 34. Drugs.com. Risperidone Dosage. 2023 (last accessed June 2024); https://www.drugs.com/dosage/risperidone.html.

No comments to display

Back to top